4.3900
-0.0100
(-0.23%)
As of 4:35:32 PM GMT+1. Market Open.
Key Executives
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in SEK.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Ms. Dorte Xenia Gram | Founder, Chairman & Chief Scientific Officer | 1.59M | -- | 1969 |
| Ms. Elna Lembrer Astrom | Chief Financial Officer | 504.9k | -- | 1961 |
| Mr. Gustav Hanghoj Gram | Chief Executive Officer | -- | -- | -- |
| Mr. Miguel Lecumberri | Head of Compliance & Legal Affairs | -- | -- | -- |
| Mr. Masoud Alavi | Head of Corporate Visual Communication | -- | -- | -- |
| Mr. Andy Makin | Head of Toxicology | -- | -- | -- |
| Ms. Maura McArdle | Head of BD & Quay Pharma | -- | -- | -- |
| Mr. Mike Frodsham | CTO of Quay Pharma | -- | -- | -- |
| Ms. Alison Foster | Head of Pre-Clinical - Quay Pharma | -- | -- | -- |
| Mr. Simon Hamilton | Head of Global Business Development - Almac | -- | -- | -- |
Pila Pharma AB (publ)
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 1
Description
PILA PHARMA AB (publ) operates as a clinical stage pharmaceutical company in Sweden. It is developing XEN-D0501, a TRPV1 antagonist that has completed two phase 2b clinical trials for type 2 diabetes. The company was incorporated in 2014 and is based in Malmö, Sweden.
Corporate Governance
Pila Pharma AB (publ)’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
Upcoming Events Information Not Available
Recent Events
Recent Events Information Not Available
Related Tickers
CANTA.ST Cantargia AB (publ)
1.8750
+1.41%
FLUO.ST FluoGuide A/S
49.70
+0.30%
BGBIO.OL BerGenBio ASA
7.90
-1.04%
GUBRA.CO Gubra A/S
662.00
+0.30%
F6T.MU Fate Therapeutics Inc
1.2810
0.00%
1BT.F Enlivex Therapeutics Ltd.
1.0500
0.00%
GYX.F Futura Medical plc
0.1750
-50.00%
1GDA.F Zevra Therapeutics, Inc.
7.65
+2.68%
HQ1.MU Oruka Therapeutics Inc. R
12.00
+5.26%
CVAC.VI CureVac N.V.
3.7140
-1.17%